Document is current
Any future updates will be listed below
-
Authors
Papavergi, Maria-Tzousi
Bathini, Praveen
Singh, Brijendra
Lemere, Cynthia A.
-
Funding
Funding for this research was provided by:
Cure Alzheimer's Fund
NIH NINDS
Brigham Research Institute
- License Information
-
More Information
Article History
Received: 17 June 2025
Accepted: 5 December 2025
First Online: 15 December 2025
Declarations
:
: Not applicable.
: Not applicable.
: C.A.L. serves or has served within the past 3 years as a consultant or SAB member for Acumen Pharmaceuticals, ADvantage Therapeutics, Alnylam Pharmaceuticals, Apellis Pharmaceuticals, Biohaven Pharmaceuticals, Cyclo Therapeutics, Eli Lilly, Merck, MindImmune Therapeutics, Novo Nordisk, Receptive Bio, Sanofi, Switch Therapeutics, and Therini Bio. All other authors have no competing interests.
